BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, August 11th

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the following two investor conferences in August 2020:

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Canada’s national healthcare regulatory agency, Health Canada, has approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with Lambert-Eaton myasthenic syndrome (LEMS),

Aditxt Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming, today introduced AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens,

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in a fireside chat at the virtual Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13, 2020 at 8:30 a.m. Eastern Time. A live audio webcast of the session will be available from the investors section of the Neo

– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviral agents progresses –

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2020 and provided a corporate update. “We continued to make significant progress across our pipeline, delivering on all milestones during the first half of the year,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences. “We are currently on track to achieve additio

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and provide a corporate update after the market close on Thursday, August 13, 2020. Conference Call and Webcast Details: Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m. PDT Domestic: 844-358-9116 Internationa

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders Biogen to receive exclusive option rights to two programs for neurodegenerative diseases utilizing Denali’s blood-brain barrier crossing TV technology platform, including for amyloid beta, plus right of first negotiation for two additional unnamed TV platform programs Denali to receive

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020, as well as recent business highlights. “Zosano is on the cusp of potentially accomplishing what few biotech companies have the privilege of doing, namely becoming a commercial organization with an approved product designed to help address a significant treatment gap,” said Steven L